Phase II trial of the impact 0.5% povidone-iodine nasal spray (Nasodine®) on shedding of SARS-CoV-2

Peter Friedland, Simon Tucker

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalThe Laryngoscope
Volume134
Publication statusAccepted/In press - 12 Mar 2024

Cite this